Daewoong Pharma
KRX:069620

Watchlist Manager
Daewoong Pharma Logo
Daewoong Pharma
KRX:069620
Watchlist
Price: 180 600 KRW -0.11% Market Closed
Market Cap: 2.1T KRW

Relative Value

The Relative Value of one Daewoong Pharma stock under the Base Case scenario is 239 115.6 KRW. Compared to the current market price of 180 600 KRW, Daewoong Pharma is Undervalued by 24%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
239 115.6 KRW
Undervaluation 24%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
30
vs Industry
71
Median 3Y
1
Median 5Y
1.1
Industry
2.6
Forward
1.4
vs History
46
vs Industry
7
Median 3Y
22.2
Median 5Y
26.6
Industry
21.7
Forward
15
vs History
41
vs Industry
16
Median 3Y
16.2
Median 5Y
19.3
Industry
16.7
vs History
69
vs Industry
25
Median 3Y
30.6
Median 5Y
27.6
Industry
23.1
vs History
39
vs Industry
43
Median 3Y
1.9
Median 5Y
2.2
Industry
2.2
vs History
17
vs Industry
65
Median 3Y
1.3
Median 5Y
1.4
Industry
2.9
Forward
1.6
vs History
30
vs Industry
65
Median 3Y
2.5
Median 5Y
2.8
Industry
5.5
vs History
47
vs Industry
35
Median 3Y
9.5
Median 5Y
11.2
Industry
13.2
Forward
10.2
vs History
53
vs Industry
33
Median 3Y
12.6
Median 5Y
15.1
Industry
16.8
Forward
12.7
vs History
39
vs Industry
12
Median 3Y
20.4
Median 5Y
21.7
Industry
15.9
vs History
vs Industry
10
Median 3Y
-17.3
Median 5Y
25.5
Industry
19.2
vs History
39
vs Industry
57
Median 3Y
1.1
Median 5Y
1.2
Industry
1.9

Multiples Across Competitors

Competitors Multiples
Daewoong Pharma Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Daewoong Pharma
KRX:069620
2.1T KRW 1.4 27.7 11.3 14.5
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55 36.9 39.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
496.6B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
259.2B CHF 4.2 27.5 11.7 13.7
UK
AstraZeneca PLC
LSE:AZN
212B GBP 4.9 30.2 108.4 158.6
CH
Novartis AG
SIX:NOVN
207B CHF 4.6 18.1 11.5 14.8
US
Merck & Co Inc
NYSE:MRK
251.4B USD 3.9 13.2 9.4 11.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.3 9.3 10.8
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
KR
Daewoong Pharma
KRX:069620
Average P/E: 24.4
27.7
98%
0.3
US
Eli Lilly and Co
NYSE:LLY
55
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.5
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
CH
Novartis AG
SIX:NOVN
18.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
Daewoong Pharma
KRX:069620
Average EV/EBITDA: 400
11.3
16%
0.7
US
Eli Lilly and Co
NYSE:LLY
36.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.4
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
Daewoong Pharma
KRX:069620
Average EV/EBIT: 1 711.5
14.5
21%
0.7
US
Eli Lilly and Co
NYSE:LLY
39.6
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.7
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.6
23%
6.9
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.2
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
8%
1.3